Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 203

1.

Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation.

Shah S, Brock EJ, Jackson RM, Ji K, Boerner JL, Sloane BF, Mattingly RR.

Neoplasia. 2018 Sep;20(9):951-963. doi: 10.1016/j.neo.2018.07.002. Epub 2018 Aug 22.

2.

In Vitro Models for Studying Invasive Transitions of Ductal Carcinoma In Situ.

Brock EJ, Ji K, Shah S, Mattingly RR, Sloane BF.

J Mammary Gland Biol Neoplasia. 2018 Jul 28. doi: 10.1007/s10911-018-9405-3. [Epub ahead of print] Review.

PMID:
30056557
3.

Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion.

Duivenvoorden HM, Rautela J, Edgington-Mitchell LE, Spurling A, Greening DW, Nowell CJ, Molloy TJ, Robbins E, Brockwell NK, Lee CS, Chen M, Holliday A, Selinger CI, Hu M, Britt KL, Stroud DA, Bogyo M, Möller A, Polyak K, Sloane BF, O'Toole SA, Parker BS.

J Pathol. 2017 Dec;243(4):496-509. doi: 10.1002/path.4990. Epub 2017 Oct 31.

PMID:
29086922
4.

A flexible Ag/AgCl micro reference electrode based on a parylene tube structure.

Zhao Z, Tu H, Kim EG, Sloane BF, Xu Y.

Sens Actuators B Chem. 2017 Aug;247:92-97. doi: 10.1016/j.snb.2017.02.135. Epub 2017 Mar 2.

5.

Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ.

Sameni M, Cavallo-Medved D, Franco OE, Chalasani A, Ji K, Aggarwal N, Anbalagan A, Chen X, Mattingly RR, Hayward SW, Sloane BF.

Breast Cancer Res. 2017 May 15;19(1):56. doi: 10.1186/s13058-017-0847-0.

6.

Live-Cell Imaging of Protease Activity: Assays to Screen Therapeutic Approaches.

Chalasani A, Ji K, Sameni M, Mazumder SH, Xu Y, Moin K, Sloane BF.

Methods Mol Biol. 2017;1574:215-225. doi: 10.1007/978-1-4939-6850-3_16.

7.

Imaging Sites of Inhibition of Proteolysis in Pathomimetic Human Breast Cancer Cultures by Light-Activated Ruthenium Compound.

Ramalho SD, Sharma R, White JK, Aggarwal N, Chalasani A, Sameni M, Moin K, Vieira PC, Turro C, Kodanko JJ, Sloane BF.

PLoS One. 2015 Nov 12;10(11):e0142527. doi: 10.1371/journal.pone.0142527. eCollection 2015.

8.

Photodynamic therapy as an effective therapeutic approach in MAME models of inflammatory breast cancer.

Aggarwal N, Santiago AM, Kessel D, Sloane BF.

Breast Cancer Res Treat. 2015 Nov;154(2):251-62. doi: 10.1007/s10549-015-3618-6. Epub 2015 Oct 26.

9.

Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.

Sameni M, Tovar EA, Essenburg CJ, Chalasani A, Linklater ES, Borgman A, Cherba DM, Anbalagan A, Winn ME, Graveel CR, Sloane BF.

Clin Cancer Res. 2016 Feb 15;22(4):923-34. doi: 10.1158/1078-0432.CCR-15-0187. Epub 2015 Oct 2.

10.

Pathomimetic cancer avatars for live-cell imaging of protease activity.

Ji K, Heyza J, Cavallo-Medved D, Sloane BF.

Biochimie. 2016 Mar;122:68-76. doi: 10.1016/j.biochi.2015.09.015. Epub 2015 Sep 12. Review.

11.

Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration.

Osuala KO, Sameni M, Shah S, Aggarwal N, Simonait ML, Franco OE, Hong Y, Hayward SW, Behbod F, Mattingly RR, Sloane BF.

BMC Cancer. 2015 Aug 13;15:584. doi: 10.1186/s12885-015-1576-3.

12.

Cathepsin B contributes to Na+ hyperabsorption in cystic fibrosis airway epithelial cultures.

Tan CD, Hobbs C, Sameni M, Sloane BF, Stutts MJ, Tarran R.

J Physiol. 2014 Dec 1;592(23):5251-68. doi: 10.1113/jphysiol.2013.267286. Epub 2014 Sep 25.

13.

Cathepsin B-deficient mice as source of monoclonal anti-cathepsin B antibodies.

Weber E, Barbulescu E, Medek R, Reinheckel T, Sameni M, Anbalagan A, Moin K, Sloane BF.

Biol Chem. 2015 Mar;396(3):277-81. doi: 10.1515/hsz-2014-0191.

14.

Cathepsin B: multiple roles in cancer.

Aggarwal N, Sloane BF.

Proteomics Clin Appl. 2014 Jun;8(5-6):427-37. doi: 10.1002/prca.201300105. Epub 2014 Mar 26. Review.

15.

Many Roles of CCL20: Emphasis on Breast Cancer.

Osuala KO, Sloane BF.

Postdoc J. 2014 Mar;2(3):7-16.

16.

Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer.

Banda M, Speyer CL, Semma SN, Osuala KO, Kounalakis N, Torres Torres KE, Barnard NJ, Kim HJ, Sloane BF, Miller FR, Goydos JS, Gorski DH.

PLoS One. 2014 Jan 3;9(1):e81126. doi: 10.1371/journal.pone.0081126. eCollection 2014.

17.

Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties.

Mohamed MM, El-Ghonaimy EA, Nouh MA, Schneider RJ, Sloane BF, El-Shinawi M.

Int J Biochem Cell Biol. 2014 Jan;46:138-47. doi: 10.1016/j.biocel.2013.11.015. Epub 2013 Nov 26.

18.

Acid-mediated tumor proteolysis: contribution of cysteine cathepsins.

Rothberg JM, Bailey KM, Wojtkowiak JW, Ben-Nun Y, Bogyo M, Weber E, Moin K, Blum G, Mattingly RR, Gillies RJ, Sloane BF.

Neoplasia. 2013 Oct;15(10):1125-37.

19.

Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression.

Bengsch F, Buck A, Günther SC, Seiz JR, Tacke M, Pfeifer D, von Elverfeldt D, Sevenich L, Hillebrand LE, Kern U, Sameni M, Peters C, Sloane BF, Reinheckel T.

Oncogene. 2014 Sep 4;33(36):4474-84. doi: 10.1038/onc.2013.395. Epub 2013 Sep 30.

20.

Cathepsin C is a tissue-specific regulator of squamous carcinogenesis.

Ruffell B, Affara NI, Cottone L, Junankar S, Johansson M, DeNardo DG, Korets L, Reinheckel T, Sloane BF, Bogyo M, Coussens LM.

Genes Dev. 2013 Oct 1;27(19):2086-98. doi: 10.1101/gad.224899.113. Epub 2013 Sep 24.

21.

Three-dimensional cultures modeling premalignant progression of human breast epithelial cells: role of cysteine cathepsins.

Mullins SR, Sameni M, Blum G, Bogyo M, Sloane BF, Moin K.

Biol Chem. 2012 Dec;393(12):1405-16.

22.

Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ.

Kaur H, Mao S, Shah S, Gorski DH, Krawetz SA, Sloane BF, Mattingly RR.

Expert Rev Mol Diagn. 2013 Mar;13(2):151-65. doi: 10.1586/erm.13.4. Review.

23.

Acidity generated by the tumor microenvironment drives local invasion.

Estrella V, Chen T, Lloyd M, Wojtkowiak J, Cornnell HH, Ibrahim-Hashim A, Bailey K, Balagurunathan Y, Rothberg JM, Sloane BF, Johnson J, Gatenby RA, Gillies RJ.

Cancer Res. 2013 Mar 1;73(5):1524-35. doi: 10.1158/0008-5472.CAN-12-2796. Epub 2013 Jan 3.

24.

RNA-Seq of human breast ductal carcinoma in situ models reveals aldehyde dehydrogenase isoform 5A1 as a novel potential target.

Kaur H, Mao S, Li Q, Sameni M, Krawetz SA, Sloane BF, Mattingly RR.

PLoS One. 2012;7(12):e50249. doi: 10.1371/journal.pone.0050249. Epub 2012 Dec 6.

25.

Deficiency in metabolic regulators PPARγ and PTEN cooperates to drive keratinizing squamous metaplasia in novel models of human tissue regeneration.

Strand DW, DeGraff DJ, Jiang M, Sameni M, Franco OE, Love HD, Hayward WJ, Lin-Tsai O, Wang AY, Cates JM, Sloane BF, Matusik RJ, Hayward SW.

Am J Pathol. 2013 Feb;182(2):449-59. doi: 10.1016/j.ajpath.2012.10.007. Epub 2012 Dec 6.

26.

The proinflammatory cytokines interleukin-1α and tumor necrosis factor α promote the expression and secretion of proteolytically active cathepsin S from human chondrocytes.

Caglič D, Repnik U, Jedeszko C, Kosec G, Miniejew C, Kindermann M, Vasiljeva O, Turk V, Wendt KU, Sloane BF, Goldring MB, Turk B.

Biol Chem. 2013 Feb;394(2):307-16. doi: 10.1515/hsz-2012-0283.

PMID:
23152404
27.

PPARα agonist Wy14643 suppresses cathepsin B in human endothelial cells via transcriptional, post-transcriptional and post-translational mechanisms.

Reichenbach G, Starzinski-Powitz A, Sloane BF, Doll M, Kippenberger S, Bernd A, Kaufmann R, Meissner M.

Angiogenesis. 2013 Jan;16(1):223-33. doi: 10.1007/s10456-012-9314-9. Epub 2012 Oct 25.

PMID:
23096928
28.

Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments.

Wojtkowiak JW, Rothberg JM, Kumar V, Schramm KJ, Haller E, Proemsey JB, Lloyd MC, Sloane BF, Gillies RJ.

Cancer Res. 2012 Aug 15;72(16):3938-47. doi: 10.1158/0008-5472.CAN-11-3881. Epub 2012 Jun 19.

29.

On how mammary gland reprogramming metalloproteinases couple form with function.

Sloane BF.

Cold Spring Harb Perspect Biol. 2012 Jul 1;4(7):a013474. doi: 10.1101/cshperspect.a013474. No abstract available.

30.

MAME models for 4D live-cell imaging of tumor: microenvironment interactions that impact malignant progression.

Sameni M, Anbalagan A, Olive MB, Moin K, Mattingly RR, Sloane BF.

J Vis Exp. 2012 Feb 17;(60). pii: 3661. doi: 10.3791/3661.

31.

3D/4D functional imaging of tumor-associated proteolysis: impact of microenvironment.

Moin K, Sameni M, Victor BC, Rothberg JM, Mattingly RR, Sloane BF.

Methods Enzymol. 2012;506:175-94. doi: 10.1016/B978-0-12-391856-7.00034-2.

32.

The cyclin-like protein Spy1/RINGO promotes mammary transformation and is elevated in human breast cancer.

Al Sorkhy M, Ferraiuolo RM, Jalili E, Malysa A, Fratiloiu AR, Sloane BF, Porter LA.

BMC Cancer. 2012 Jan 26;12:45. doi: 10.1186/1471-2407-12-45.

33.

Cathepsin B inhibition limits bone metastasis in breast cancer.

Withana NP, Blum G, Sameni M, Slaney C, Anbalagan A, Olive MB, Bidwell BN, Edgington L, Wang L, Moin K, Sloane BF, Anderson RL, Bogyo MS, Parker BS.

Cancer Res. 2012 Mar 1;72(5):1199-209. doi: 10.1158/0008-5472.CAN-11-2759. Epub 2012 Jan 19.

34.

Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion.

Victor BC, Anbalagan A, Mohamed MM, Sloane BF, Cavallo-Medved D.

Breast Cancer Res. 2011;13(6):R115. doi: 10.1186/bcr3058. Epub 2011 Nov 17.

35.

Live-cell imaging of tumor proteolysis: impact of cellular and non-cellular microenvironment.

Rothberg JM, Sameni M, Moin K, Sloane BF.

Biochim Biophys Acta. 2012 Jan;1824(1):123-32. doi: 10.1016/j.bbapap.2011.07.025. Epub 2011 Aug 5. Review.

36.

Aborted autophagy and nonapoptotic death induced by farnesyl transferase inhibitor and lovastatin.

Wojtkowiak JW, Sane KM, Kleinman M, Sloane BF, Reiners JJ Jr, Mattingly RR.

J Pharmacol Exp Ther. 2011 Apr;337(1):65-74. doi: 10.1124/jpet.110.174573. Epub 2011 Jan 12.

37.

Cathepsin B: a potential prognostic marker for inflammatory breast cancer.

Nouh MA, Mohamed MM, El-Shinawi M, Shaalan MA, Cavallo-Medved D, Khaled HM, Sloane BF.

J Transl Med. 2011 Jan 3;9:1. doi: 10.1186/1479-5876-9-1.

38.

Capturing and characterizing immune cells from breast tumor microenvironment: an innovative surgical approach.

El-Shinawi M, Abdelwahab SF, Sobhy M, Nouh MA, Sloane BF, Mohamed MM.

Ann Surg Oncol. 2010 Oct;17(10):2677-84. doi: 10.1245/s10434-010-1029-9. Epub 2010 Mar 24.

39.

Interleukin-6 increases expression and secretion of cathepsin B by breast tumor-associated monocytes.

Mohamed MM, Cavallo-Medved D, Rudy D, Anbalagan A, Moin K, Sloane BF.

Cell Physiol Biochem. 2010;25(2-3):315-24. doi: 10.1159/000276564. Epub 2010 Jan 12.

40.

Chiral porphyrazine near-IR optical imaging agent exhibiting preferential tumor accumulation.

Trivedi ER, Harney AS, Olive MB, Podgorski I, Moin K, Sloane BF, Barrett AG, Meade TJ, Hoffman BM.

Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1284-8. doi: 10.1073/pnas.0912811107. Epub 2009 Dec 23.

41.

Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ.

Jedeszko C, Victor BC, Podgorski I, Sloane BF.

Cancer Res. 2009 Dec 1;69(23):9148-55. doi: 10.1158/0008-5472.CAN-09-1043. Epub 2009 Nov 17.

42.

Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis.

Podgorski I, Linebaugh BE, Koblinski JE, Rudy DL, Herroon MK, Olive MB, Sloane BF.

Am J Pathol. 2009 Sep;175(3):1255-69. doi: 10.2353/ajpath.2009.080906. Epub 2009 Aug 21.

43.

Microarrays for protease detection in tissues and cells.

Moin K, Schwartz D, Mullins SR, Sloane BF.

Methods Mol Biol. 2009;539:49-57. doi: 10.1007/978-1-60327-003-8_3.

44.

Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation.

Cavallo-Medved D, Rudy D, Blum G, Bogyo M, Caglic D, Sloane BF.

Exp Cell Res. 2009 Apr 15;315(7):1234-46. doi: 10.1016/j.yexcr.2009.01.021. Epub 2009 Feb 3.

45.

Bicarbonate increases tumor pH and inhibits spontaneous metastases.

Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Dosescu J, Sloane BF, Hashim AI, Morse DL, Raghunand N, Gatenby RA, Gillies RJ.

Cancer Res. 2009 Mar 15;69(6):2260-8. doi: 10.1158/0008-5472.CAN-07-5575. Epub 2009 Mar 10.

46.

Functional live-cell imaging demonstrates that beta1-integrin promotes type IV collagen degradation by breast and prostate cancer cells.

Sameni M, Dosescu J, Yamada KM, Sloane BF, Cavallo-Medved D.

Mol Imaging. 2008 Sep-Oct;7(5):199-213.

47.

Cathepsin B protein levels in endometrial cancer: Potential value as a tumour biomarker.

Devetzi M, Scorilas A, Tsiambas E, Sameni M, Fotiou S, Sloane BF, Talieri M.

Gynecol Oncol. 2009 Mar;112(3):531-6. doi: 10.1016/j.ygyno.2008.10.030. Epub 2008 Dec 24.

PMID:
19110306
48.

Imaging and quantifying the dynamics of tumor-associated proteolysis.

Sameni M, Cavallo-Medved D, Dosescu J, Jedeszko C, Moin K, Mullins SR, Olive MB, Rudy D, Sloane BF.

Clin Exp Metastasis. 2009;26(4):299-309. doi: 10.1007/s10585-008-9218-7. Epub 2008 Dec 13. Review.

49.

Lysosomal cathepsin B participates in the podosome-mediated extracellular matrix degradation and invasion via secreted lysosomes in v-Src fibroblasts.

Tu C, Ortega-Cava CF, Chen G, Fernandes ND, Cavallo-Medved D, Sloane BF, Band V, Band H.

Cancer Res. 2008 Nov 15;68(22):9147-56. doi: 10.1158/0008-5472.CAN-07-5127.

50.

Human monocytes augment invasiveness and proteolytic activity of inflammatory breast cancer.

Mohamed MM, Cavallo-Medved D, Sloane BF.

Biol Chem. 2008 Aug;389(8):1117-21. doi: 10.1515/BC.2008.117.

Supplemental Content

Loading ...
Support Center